What Fred Said: Schering-Plough's Hassan On Life In Big Pharma
Executive Summary
Fred Hassan's days as chairman of Schering-Plough are numbered, and he hasn't indicated his next step once his company's merger with Merck closes, likely later this year. He remained cagey - giving only a few indirect clues about his preferences in an interview held Sept. 23 as part of Windhover's Pharmaceutical Strategic Alliances conference in New York City
You may also be interested in...
Get Attitude, Drive Cultural Transformation, Fred Hassan Tells Execs At TAP
Cultural transformation was the main topic of Warburg Pincus managing director Fred Hassan’s keynote talk at the Therapeutic Area Partnerships meeting on Nov. 19, where the audience also drew on the investor’s extensive track record leading some of pharma’s most successful turnarounds.
Pfizer, J&J See Promise, Make Investment in Cancer Device Company
Pfizer's venture group invested alongside Johnson & Johnson Development Corp. and Index Ventures in NovoCure Ltd., a device company developing a treatment to bolster the affect of chemotherapies.
Pfizer, J&J See Promise, Make Investment in Cancer Device Company
Pfizer's venture group invested alongside Johnson & Johnson Development Corp. and Index Ventures in NovoCure Ltd., a device company developing a treatment to bolster the affect of chemotherapies.